@article {1543,
	title = {An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly.},
	journal = {Nature Biotechnology},
	volume = {24},
	year = {2006},
	month = {2006 Mar},
	pages = {358-62},
	abstract = {<p>Virus assembly has not been routinely targeted in the development of antiviral drugs, in part because of the lack of tractable methods for screening in vitro. We have developed an in vitro assay of hepatitis B virus (HBV) capsid assembly, based on fluorescence quenching of dye-labeled capsid protein, for testing potential inhibitors. This assay is adaptable to high-throughput screening and can identify small-molecule inhibitors of virus assembly that prevent, inappropriately accelerate and/or misdirect capsid formation to yield aberrant particles. An in vitro primary screen has the advantage of identifying promising lead compounds affecting assembly without the requirement that they be taken up by cells in culture and be nontoxic. Our approach may facilitate the identification of antivirals targeting viruses other than HBV, such as avian influenza and HIV.</p>
},
	keywords = {Antiviral Agents, Biological Assay, Boron Compounds, Capsid, Capsid Proteins, Dimerization, Fluorescence, Fluorescent Dyes, Hepatitis B virus, Kinetics, Light, Models, Molecular, Radiation, Scattering, Virus Assembly},
	issn = {1087-0156},
	doi = {10.1038/nbt1187},
	author = {Stray, Stephen J and Johnson, Jennifer M and Kopek, Benjamin G and Zlotnick, Adam}
}
